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Abstract
Background: Mucinous ovarian carcinoma have a poorer prognosis compared with other
histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of
chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer.
Methods: The SOCRATES study retrospectively assessed the pattern of care of a cohort of
patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000–2002 in 37
Italian centres. Data were collected between April and September 2005. Patients with recurrent
ovarian cancer with > 6 months of platinum free interval were considered eligible.
Results: Twenty patients with mucinous histotype and 388 patients with other histotypes were
analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients
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with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of
recurrence, a statistically significant difference was found in performance status (worse in
mucinous, p = 0.024). About 20% of patients underwent secondary cytoreduction in both groups,
but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients
with mucinous cancer received more frequently single agent platinum than platinum based-
combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a
response rate lower than in non-mucinous group (36.4% vs 62.6%, respectively, p = 0.04). Median
time to progression and overall survival were worse for mucinous ovarian cancer. Finally, mucinous
cancer received a lower number of chemotherapy lines (p = 0.0023).
Conclusion: This analysis shows that platinum sensitive mucinous ovarian cancer has a poor
response to chemotherapy. Studies dedicated to this histological subgroup are needed.
Background
Mucinous carcinoma of the ovary accounts for 5–10% of
all primary epithelial ovarian cancer [1]. Patients with
mucinous ovarian cancer generally undergo the same
first- and second-line treatment as patients with other his-
tological subtypes [2]. However, very few reports in the lit-
erature have been published on this topic and activity of
chemotherapy has been described in a limited number of
patients and only in the first-line setting [3-6]. It has
recently been shown in two different series of 27 and 45
patients, that advanced mucinous ovarian carcinoma have
a poor response to first line chemotherapy [3,6]. Thus,
resistance to chemotherapy has been claimed as one of the
main cause of the worse prognosis of mucinous ovarian
cancer [3].
The SOCRATES (Study of an Ovarian Cancer cohort
Recurred After first-line Treament: a rEstrospectivy Sur-
vey) study was planned to retrospectively assess the pat-
tern of care of patients with recurrent platinum-sensitive
ovarian cancer observed in Italy in the years 2000–2002
[7]. Using this cohort of patients we evaluated the
response of mucinous cancer to chemotherapy in the
recurrent setting.
Methods
Patients with recurrent advanced ovarian cancer and a
recurrence free interval (RFI) longer than 6 months were
considered eligible for the study. The patients were
observed in the years 2000–2002 in 37 Italian centres.
Data were collected between April and September 2005.
Four-hundred-ninety-three patient files were screened
and 408 were considered eligible and analyzed in the
present study.
The descriptive analysis of the data has been performed in
2 different subgroups identified according to histology:
mucinous cancer and non-mucinous cancer. No central
pathology assessment of the cancer samples was done.
Clinical, pathological and treatment characteristics at ini-
tial diagnosis, as well as at recurrence, including surgical
and medical treatment (up to 6 lines of chemotherapy) of
the recurrence were considered. Response rate was calcu-
lated considering RECIST [8] or Ca 125 criteria [9].
Overall survival was defined as the time elapsed between
recurrence diagnosis and the date of death or the date of
last follow-up information for live patients. Time to pro-
gression and overall survival were described y the Kaplan-
Meier product limit method [10].
Differences among baseline variables were analyzed by
the Student t test and Wilcoxon rank test for quantitative
variables, and by the Mantel Haenszel test and the Chi-
square method for the qualitative variables. Differences
were considered statistically significant when p < 0.05.
All analysis was done using SAS® (SAS Institute Inc., Cary,
NC, USA-version 9.1.3) statistical software.
Results
Mucinous tumors were diagnosed in 20 patients, as com-
pared with 388 patients with other histological subtypes
(table 1). Median age, performance status, results of pri-
mary surgery were similar between the two groups. In
mucinous ovarian cancer, the grading of the tumors was
lower than in the other subtypes (p = 0.0056) and stage at
diagnosis was less advanced (p = 0.025)
The main characteristics of the patients at time of recur-
rence are shown in table 2. A statistically significant differ-
ence was found in performance status, that was worse in
the mucinous group (p = 0.024), while no differences
were found in the number of disease sites, age and recur-
rence free interval.
About 20% of patients underwent secondary cytoreduc-
tion in both groups, with a lower number of patients opti-
mally debulked (no residual disease) in the group of
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patients with mucinous cancer (p = 0.03). The majority of
patients with mucinous tumours had increased CA 125
levels at recurrence (85%).
Details on second-line chemotherapy are shown in the
table 3. Patients with mucinous cancer received as second
line therapy more frequently single agent platinum
(42.1%) than platinum-combination therapy (31.6%) or
other non-platinum chemotherapy (26.3%) (p = 0.026).
The response rate (CR + PR) to the second line chemother-
apy was lower in mucinous cancer than in non-mucinous
one (36.4% vs 62.6%, respectively, p = 0.04). Moreover,
patients with mucinous cancer received a lower number of
lines of chemotherapy as compared to the other histo-
types (p = 0.0023). Median progression free survival was
4.5 months in the mucinous and 8 months in non-muci-
nous group (p = 0.0292). Overall median survival from
recurrence was 17.9 months in the mucinous and 28.8
months in non-mucinous group (p = 0.0028) (Figure 1).
In the mucinous cancer group responses were obtained
with carboplatin, cisplatin, and carboplatin/paclitaxel (2
responses in patients with 6–12 months and 2 responses
in patients with > 12 recurrence free interval). Among
patients treated with non platinum-agents, no response
was observed at second line, while responses were
achieved in third-fourth line with paclitaxel (1/2
patients), topotecan (1/4 patients) and cyclophospha-
mide (1/1); no activity was observed with liposomal dox-
orubicin (0/4 patients) and gemcitabine (0/1 patient).
Discussion
This retrospective study indicates that recurrent mucinous
ovarian cancer has a lower response rate to chemotherapy
Table 1: Characteristics of the patients with recurrent mucinous ovarian cancer compared to other histological subtypes at the time of 
initial diagnosis of ovarian cancer.
Mucinous Other histotypes p
Number of patients 20 388
Age (years) 20 384 n.s.*
Mean (± s.d.) 54.9 ± 12.5 57.7 ± 10.8
median 55 57
range 25–71 31–94
FIGO stage at diagnosis 20 383
I 20.0% 6.5% 0.0258**
II 10.0% 7.3%
III 65.0% 77.0%
IV 5.0% 9.1%
Grading 12 348
1 25.0% 3.4% 0.0056**
2 16.7% 24.7%
3 58.3% 71.8%
Result of cytoreductive surgery 15 319
No residual disease 46.7% 26.0% n.s.**
Optimal (d 1 cm residual disease) 20.0% 29.5%
Suboptimal (> 1 cm residual disease) 33.3% 44.5%
ECOG performance status 15 347
0 60.0% 68.3% n.s.**
1 33.3% 26.5%
2 6.7% 4.3%
3 . 0.9%
Type of first line chemotherapy 20 338 n.s.***
Platinum single agent 15.0% 11.1%
Platinum based combinations 85.0% 88.9%
• t-test; ** F2 Mantel-Haenszel; *** F2
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and a worst prognosis compared to non-mucinous sub-
types. Moreover, patients receive less chemotherapy lines
for recurrence as compared to other histotypes and when
undergo secondary cytoreduction, this is less effective. At
our knowledge, this analysis describes for the first time the
response rate to second line chemotherapy in patients
with platinum sensistive mucinous ovarian cancer. At
baseline, the only main characteristic differentiating
mucinous from non-mucinous tumour was the lower
grade of the cancer, according to what previously observed
[4]. Although we have not enough data to state that the
poor response to chemotherapy is related to the lower
grade of the tumours, it is possible to speculate that recur-
rent low grade cancer may benefit from a more aggressive
attempt of cytoreduction before medical therapy. Unfor-
tunately, in our series the patients that underwent second-
ary cytoreduction did not achieve the goal of obtaining an
absence of residual disease; of course, the small number of
patients does not allow to reach a definitive conclusion
regarding the role of surgery in the treatment of recurrent
mucinous ovarian cancer. No other disease related charac-
teristics differed between mucinous and non-mucinous
patients at recurrence.
Mucinous carcinomas of the ovary includes 5–10% of
ovarian carcinomas, although recent refinements in the
interpretation of the histological features of noninvasive
and metastatic mucinous carcinomas suggest that this
may be an overestimate [1,11]. Clinical stage is the most
important predictor of survival in mucinous ovarian car-
cinoma. The early stages confer a better overall prognosis
for survival [11,12], while the advanced disease has been
associated with a poorer survival compared to the other
histological subgroups [11-13].
The rarity of the disease is the main reason of the paucity
of literature data regarding the activity of chemotherapy in
this entity. Cloven [14] have shown, "in vitro", that the fre-
Table 2: Characteristics of patients with mucinous ovarian cancer with a recurrence free interval > 6 months compared to other 
histological subtypes at the time of the diagnosis of recurrence.
Mucinous Other histotypes p
Number of patients 20 388
Age (years) 20 380
Mean (± s.d.) 57.6 ± 12.8 59.8 ± 10.8 n.s.*
Median 58 60.5
Range 28–78 33–97
PS Ecog 20 360
0 45.0% 62.8% 0.0241**
1 40.0% 33.9%
2 15.0% 3.3%
3 . . .
Recurrence free interval (N) 17 378
6–12 months 58.8% 38.9% n.s.**
> 12 months 41.2% 61.1%
median (range) – months: 10.6 (5–141) 15.3 (5–160) n.s.****
Number of disease sites 20 335
1 25.0% 44.8% n.s.**
> 1 75.0% 55.2%
Surgery 19 375
Yes 26.3% 20.5% n.s.***
No 73.7% 79.5%
Result of cytoreductive surgery 5 64
No residual . 50.0% 0.0308***
Residual desease 100.0% 50.0%
Ca 125 14 247 n.s.**
Normal: d 35 14.3% 12.1%
> 35 U/ml 85.7% 87.9%
* t-test; ** F2 Mantel-Haenszel; *** F2; ****Wilcoxon
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quency of extreme drug resistance to chemotherapeutic
agents differs significantly among histological subtypes of
epithelial ovarian cancer. These authors demonstrated
that mucinous ovarian cancer cells are more frequently
resistant to cisplatin, but less frequently resistant to topo-
tecan and doxorubicin compared to papillary serous
tumors [14], however clinical data are lacking.
In a case-controlled study Hess [3] showed, on 27 muci-
nous and 54 other histological types,, that patients with
advanced mucinous ovarian cancer have a poorer
response to platinum-based first-line chemotherapy com-
pared with patients with other histological subtypes,
along with a worse survival. In this series, only 37% of the
patients were treated with carboplatin/paclitaxel combi-
Table 3: Response to second line chemotherapy in patients with mucinous ovarian cancer with a recurrence free interval > 6 months 
compared to other histological subtypes
Mucinous Other histotypes p
N pts. 20 388
Type of second line chemotherapy 19 384
Platinum single agent (8) 42.1% (67) 17.4% 0.0259*
Platinum based combination (6) 31.6% (184) 47.9%
No platinum (5) 26.3% (133) 34.6%
Response rate to second line
All evaluable patients 11 340
CR + PR (4) 36.4% (213) 62.6% 0.0407*
Platinum 7 227
CR + PR (4) 57.1% (170) 74.9% n.s.*
Non-platinum 4 113
CR + PR (-) 0% (43) 38.1% n.s.*
Number of chemotherapy lines received for recurrence
Mean (± s.d.) 1.9 ± 1.1 2.8 + 1.3 0.0023**
* F2; **t-test
Overall survival from recurrence in patients with mucinous ( ) compared to other histotypes (n)Figure 1
Overall survival from recurrence in patients with mucinous (r) compared to other histotypes (n).
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nation as first-line treatment, while the remainder
received carboplatin alone or platinum plus anthracy-
clines. The overall response rate was 26% in first-line
chemotherapy, while the response rate in second- and
third-line chemotherapy was not reported [3]. A poor
response to first line chemotherapy has been described by
the Hellenic Cooperative Group [6]. In a previous study,
we also showed in 21 consecutive patients with mucinous
ovarian cancer treated in a single institution that the
response rate to first line chemotherapy was significantly
lower than that found in the other histological subgroups,
with paclitaxel being the only drug showing activity in sec-
ond line [4].
Platinum-sensitive recurrent ovarian cancer is usually
treated with carboplatin/paclitaxel or carboplatin/gemcit-
abine, based on the trials showing superiority of combina-
tion chemotherapy versus single agent carboplatin
[15,16]. In our study an higher proportion of patients
with mucinous cancer was treated at recurrence with sin-
gle agent platinum than with platinum based combina-
tion therapy or other non platinum agents. Data clearly
indicate that patients with recurrent mucinous ovarian
cancer with a recurrence free interval higher than 6
months can respond to a platinum re-treatment, although
the response rate is lower than that observed in non-muci-
nous cancer. Overall, recurrent mucinous cancer patients
receive less chemotherapy lines than the others, probably
also due to the lack of data in the literature showing activ-
ity for the chemotherapy agents more frequently used in
this disease.
Here we report for the first time some responses to paclit-
axel, topotecan and cyclophosphamide, while no
response was observed with liposomal doxorubicin and
gemcitabine. Overall the response rate to non-platinum
agents was quite poor.
A possible limitation of our report is the retrospective
nature of the analysis: therefore, survival data should be
interpreted with caution. Another weakness of the study
may be the lack of a central pathology review, to confirm
these were mucinous ovarian cancers versus metastatic
malignancies of gastrointestinal origin. However, the dif-
ferential diagnosis between gastrointestinal and ovarian
cancer is a major problem at time of initial diagnosis. In
fact, in the case of our series of recurrent ovarian cancer
this limitation may be less important since it is likely that
during the disease free interval the potential presence of a
primary gastrointestinal cancer would have been diag-
nosed. Moreover, a worse performance status was found
in patients with mucinous tumors: however, due to the
small number of patients, no definite conclusions can be
drawn regarding the potential effect of performance status
on the poor survival of patients with mucinous tumors.
Conventional parameters used to predict the clinical
behaviour of advanced ovarian cancer may not adequately
correlate with prognosis in mucinous carcinoma. Several
studies have shown that mucinous ovarian cancer has a
different pattern of expression of some molecular factors
compared to the other subtypes. It is possible that a better
understanding of tumour biology may help in determin-
ing which patients with mucinous ovarian cancer would
benefit from traditional chemotherapy or should receive
alternative chemotherapy agents. Several studies have
shown that RAS mutations (specifically at KRAS codon
12) are prevalent in ovarian cancers of mucinous histol-
ogy but not in tumors of non-mucinous histologies
[17,19]. On the contrary, mutation of p53, which is con-
sidered important in defining sensitivity to paclitaxel, is
less frequent in mucinous tumors [20]. Again, some stud-
ies have found that the expression of COX-2 was much
less frequent in mucinous cancer than in serous and
endometroid ovarian cancers [21,22]. Chemotherapy
decisions tailored to the biology of mucinous ovarian can-
cer should be investigated in the future. The rarity of the
disease should not discourage the assessment, in clinical
trials, of the activity of different drugs, choosing first
among those active in gastrointestinal cancer. Further-
more, "in vitro" drug response assays could be very useful
to select patients that are likely to be resistant to tradi-
tional chemotherapy for whom to suggest an alternative,
experimental treatment.
Conclusion
In conclusion, we showed that mucinous ovarian cancer
has a poor response to chemotherapy in the recurrence
setting along with a worst prognosis. Responses to plati-
num re-treatment are less frequent than in non-mucinous
cancer, while anecdotal responses occur with non-plati-
num agents. Studies with alternative chemotherapy com-
binations are mandatory in this histological subgroup.
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